🇺🇸 Structolipid in United States

11 US adverse-event reports

Marketing authorisation

FDA

• Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 11

Most-reported reactions

1. Pneumonia — 2 reports (18.18%)
2. Anaemia — 1 report (9.09%)
3. Back Pain — 1 report (9.09%)
4. Blood Pressure Decreased — 1 report (9.09%)
5. Bone Marrow Failure — 1 report (9.09%)
6. C-Reactive Protein Increased — 1 report (9.09%)
7. Chest Discomfort — 1 report (9.09%)
8. Condition Aggravated — 1 report (9.09%)
9. Confusional State — 1 report (9.09%)
10. Device Related Sepsis — 1 report (9.09%)

Source database →

Frequently asked questions

Is Structolipid approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Structolipid in United States?

Huazhong University of Science and Technology is the originator. The local marketing authorisation holder may differ — check the official source linked above.